These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37847051)

  • 1. A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product.
    Dowdy SF; Gallagher CJ; Vitarella D; Brown J
    Expert Opin Drug Deliv; 2023; 20(9):1157-1166. PubMed ID: 37847051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A.
    Solish N; Carruthers J; Kaufman J; Rubio RG; Gross TM; Gallagher CJ
    Drugs; 2021 Dec; 81(18):2091-2101. PubMed ID: 34787840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines.
    Humphrey S; Dover JS; Bowsher RR; Clancy A; Liu Y; Prawdzik G; Gallagher CJ
    Aesthet Surg J; 2023 Sep; 43(10):1189-1193. PubMed ID: 37051886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials.
    Gallagher CJ; Bowsher RR; Clancy A; Dover JS; Humphrey S; Liu Y; Prawdzik G
    Toxins (Basel); 2023 Jan; 15(1):. PubMed ID: 36668880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical Stability and Microbial Control of Reconstituted DaxibotulinumtoxinA-lanm for Injection.
    Ellis K; Thach T; Gallagher CJ
    Toxins (Basel); 2023 Dec; 15(12):. PubMed ID: 38133187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DaxibotulinumtoxinA-lanm (Daxxify™): A Comprehensive Overview.
    Salame N; Eber AE; Dover J
    Skin Therapy Lett; 2023 Jul; 28(4):1-3. PubMed ID: 37440610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell penetrating peptides: the potent multi-cargo intracellular carriers.
    Kardani K; Milani A; H Shabani S; Bolhassani A
    Expert Opin Drug Deliv; 2019 Nov; 16(11):1227-1258. PubMed ID: 31583914
    [No Abstract]   [Full Text] [Related]  

  • 8. A reversible cell penetrating peptide-cargo linkage allows dissection of cell penetrating peptide- and cargo-dependent effects on internalization and identifies new functionalities of putative endolytic peptides.
    Morris DP; Snipes LC; Hill SA; Woods MM; Mbugua MM; Wade LR; McMurry JL
    Front Pharmacol; 2022; 13():1070464. PubMed ID: 36479201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Cargo Identity Alters the Uptake of Cell-Penetrating Peptide (CPP)/Cargo Complexes: A Study on the Effect of Net Cargo Charge and Length.
    Hymel HC; Rahnama A; Sanchez OM; Liu D; Gauthier TJ; Melvin AT
    Cells; 2022 Apr; 11(7):. PubMed ID: 35406759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct transduction modes of arginine-rich cell-penetrating peptides for cargo delivery into tumor cells.
    Ma DX; Shi NQ; Qi XR
    Int J Pharm; 2011 Oct; 419(1-2):200-8. PubMed ID: 21843610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore.
    Trofimenko E; Grasso G; Heulot M; Chevalier N; Deriu MA; Dubuis G; Arribat Y; Serulla M; Michel S; Vantomme G; Ory F; Dam LC; Puyal J; Amati F; Lüthi A; Danani A; Widmann C
    Elife; 2021 Oct; 10():. PubMed ID: 34713805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cationic PTD/CPP-mediated macromolecular delivery: charging into the cell.
    Lönn P; Dowdy SF
    Expert Opin Drug Deliv; 2015; 12(10):1627-36. PubMed ID: 25994800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabrication, characterization and evaluation of a new designed botulinum toxin-cell penetrating peptide nanoparticulate complex.
    Ravari NS; Sheikhlou MG; Goodarzi N; Kharazian B; Amini M; Atyabi F; Nasrollahi SA; Dinarvand R
    Daru; 2023 Jun; 31(1):1-12. PubMed ID: 37209247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Penetrating Peptides: A Powerful Tool for Targeted Drug Delivery.
    Kotadiya DD; Patel P; Patel HD
    Curr Drug Deliv; 2024; 21(3):368-388. PubMed ID: 37026498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a non-cationic cell penetrating peptide derived from membrane-interacting human proteins and its potential as a protein delivery carrier.
    Young Kim H; Young Yum S; Jang G; Ahn DR
    Sci Rep; 2015 Jun; 5():11719. PubMed ID: 26114640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent in vivo advances in cell-penetrating peptide-assisted drug delivery.
    Kurrikoff K; Gestin M; Langel Ü
    Expert Opin Drug Deliv; 2016; 13(3):373-87. PubMed ID: 26634750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy.
    Mo RH; Zaro JL; Shen WC
    Mol Pharm; 2012 Feb; 9(2):299-309. PubMed ID: 22171592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complexing Protein-Free Botulinum Neurotoxin A Formulations: Implications of Excipients for Immunogenicity.
    Martin MU; Frevert J; Tay CM
    Toxins (Basel); 2024 Feb; 16(2):. PubMed ID: 38393178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular delivery of noncovalently-associated macromolecules by cell-penetrating peptides.
    Chang M; Huang YW; Aronstam RS; Lee HJ
    Curr Pharm Biotechnol; 2014; 15(3):267-75. PubMed ID: 24938892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches for the discovery of new cell-penetrating peptides.
    Porosk L; Gaidutšik I; Langel Ü
    Expert Opin Drug Discov; 2021 May; 16(5):553-565. PubMed ID: 33874824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.